Naproxen Fails to Get FDA Heart Safety Nod

Health Care Comments Off

Members of two FDA advisory committees meeting jointly rejected a change in the label on naproxen to reflect a lower cardiovascular risk compared with other NSAIDS. Recent evidence convinced nine of the panelists that naproxen carries a lower risk versus others drugs in the class, but failed to sway 16 others.